TOP2A Expression in Pheochromocytoma and Abdominal Paraganglioma: a Marker of Poor Clinical Outcome?
AbstractPheochromocytoma and abdominal paraganglioma (PPGL) are rare neuroendocrine tumors originating from chromaffin cells. Even though only 10 –15% of the tumors metastasize, all PPGLs are considered potentially malignant. Topoisomerase 2A (TOP2A) is a protein involved in cell proliferation and has been found to be over-expressed in metastatic PPGL. To provide support whether TOP2A could serve as a prognostic marker, 88 PPGLs (of which 8 metastatic/relapsing) and 10 normal adrenal gland samples were assessed forTOP2A mRNA expression using quantitative real-time PCR (qRT-PCR) and TOP2A immunohistochemistry. Comparisons...
Source: Endocrine Pathology - January 19, 2023 Category: Pathology Source Type: research
Infiltrative Growth Predicts the Risk of Recurrence After Surgery in Well-Differentiated Non-Functioning Pancreatic Neuroendocrine Tumors
AbstractThe incidence of well-differentiated non-functioning pancreatic neuroendocrine tumors (NF-PanNET) increased during the last decades. The risk of relapse after curative surgery, albeit low, is not negligible; moreover, adjuvant treatment is currently not an option and a reliable predictive model based on prognostic characteristics is urgently needed for tailoring a follow-up strategy. The histological classification of PanNET now relies only on the proliferative activity (mitosis and Ki67) and staging. In contrast to other endocrine neoplasms, the role of infiltrative growth pattern in NF-PanNET is not taken into co...
Source: Endocrine Pathology - December 24, 2022 Category: Pathology Source Type: research
The Significance of Unsampled Microscopic Thyroid Carcinomas in Multinodular Goiter
This study aims to investigate the frequency and clinical significance of initially unsampled microscopic thyroid carcinomas in total thyroidectomy specimens with presumed benign multinodular thyroid disease. Seventy-two total thyroidectomy specimens belonging to multinodular goiter patients were randomly selected and included in this prospectively designed study. Inclusion criteria were set as no suspicion of malignancy before surgery as well as lack of intra-parenchymal primary thyroid carcinoma after histopathological evaluation of slides generated from initial sampling. Subsequently, the remaining thyroidectomy specime...
Source: Endocrine Pathology - December 17, 2022 Category: Pathology Source Type: research
Menin Loss in Pheochromocytoma of Multiple Endocrine Neoplasia Type 1
(Source: Endocrine Pathology)
Source: Endocrine Pathology - December 15, 2022 Category: Pathology Source Type: research
Abstracts of the 15th International VHL Medical/Research Symposium
(Source: Endocrine Pathology)
Source: Endocrine Pathology - November 21, 2022 Category: Pathology Source Type: research
Correction to: Kinase Fusion –Related Thyroid Carcinomas: Towards Predictive Models for Advanced Actionable Diagnostics
(Source: Endocrine Pathology)
Source: Endocrine Pathology - November 21, 2022 Category: Pathology Source Type: research
The Spectrum of Familial Pituitary Neuroendocrine Tumors
In conclusion, PitNETs may occur in relation to well-established familial germline mutations which may determine the clinical phenotype and the response to treatment, and may require family screening. (Source: Endocrine Pathology)
Source: Endocrine Pathology - November 18, 2022 Category: Pathology Source Type: research
Primary Thyroid Mucoepidermoid Carcinoma (MEC) Is Clinically, Prognostically, and Molecularly Different from Sclerosing MEC with Eosinophilia: A Multicenter and Integrated Study
In conclusion, MECs and SMECEs not only shared some similarities but also demonstrated differences in clinicopathological characteristics, prognoses, and molecular profiles. SMECEs had a superior DSS in comparison to MECs, suggesting that they are low-grade cancers. This could help cl inicians better evaluate patient outcomes and decide appropriate treatment plans. (Source: Endocrine Pathology)
Source: Endocrine Pathology - November 17, 2022 Category: Pathology Source Type: research
Recipient of the 2022 Endocrine Pathology Society Lifetime Achievement Award: Dr. Virginia Anne LiVolsi, M.D
(Source: Endocrine Pathology)
Source: Endocrine Pathology - November 3, 2022 Category: Pathology Source Type: research
Kinase Fusion –Related Thyroid Carcinomas: Towards Predictive Models for Advanced Actionable Diagnostics
AbstractThe past decade has brought significant advances in our understanding of the molecular mechanisms of thyroid carcinogenesis. Among thyroid carcinomas, the most successful class of targeted therapeutics appears to be selective kinase inhibitors. Actionable kinase fusions arise in around 10 –15% of cases of thyroid cancer, a significant subset. A cohort of molecular testing platforms, both commercial and laboratory-derived, has been introduced into clinical practice to identify patients with targetable tumors, requiring pathologists to develop an integrative approach that utilizes tr aditional diagnostic cytopathol...
Source: Endocrine Pathology - October 29, 2022 Category: Pathology Source Type: research
DICER1 Mutations Occur in More Than One-Third of Follicular-Patterned Pediatric Papillary Thyroid Carcinomas and Correlate with a Low-Risk Disease and Female Gender Predilection
AbstractSome pediatric papillary thyroid carcinoma (PPTC) cohorts have suggested a preliminary correlation with respect toDICER1 mutation status and histomorphology in both benign and malignant follicular cell –derived nodules; however, the data regarding correlates ofDICER1-related sporadic PPTCs subtyped based on the 2022 WHO classification criteria are largely unavailable. The current study investigated the status of hotspotDICER1 mutations with clinical, histological and outcome features in a series of 56 patients with PPTCs with no clinical or family history of DICER1-related syndromic manifestation. Fifteen (27%) P...
Source: Endocrine Pathology - October 17, 2022 Category: Pathology Source Type: research
Histopathological Features of Pendred Syndrome Thyroids Align with Differences in the Expression of Thyroid-Specific Markers, Apical Iodide Transporters, and Ciliogenesis Process
AbstractPendred syndrome (PDS) is an autosomal recessive disorder caused by mutations in the gene that encodes pendrin. Pendred thyroid tissue is supposedly altered by the absence of functional pendrin, but it is still unknown whether other iodide exchangers could compensate for the loss of the protein. Moreover, we have recently described that primary cilium, a conserved structure present at the apical surface of normal follicular cells, suffers different alterations in functional thyroid diseases. We aimed (1) to better understand the histopathological changes experienced by PDS thyroids, (2) to analyze the expression ...
Source: Endocrine Pathology - October 15, 2022 Category: Pathology Source Type: research
Papillary Thyroid Carcinoma with Desmoid-Like Fibromatosis: Double Trouble?
(Source: Endocrine Pathology)
Source: Endocrine Pathology - October 15, 2022 Category: Pathology Source Type: research
A Matched-Pair Analysis of Nuclear Morphologic Features Between Core Needle Biopsy and Surgical Specimen in Thyroid Tumors Using a Deep Learning Model
In conclusion, tumor cells in CNB showed marked nuclear shrinkage, darker nuclear staining, and nuclear vacuolar changes. Awareness of the morphological differences according to the sampling types can facilitate correct diagnosis in thyroid histopathology. (Source: Endocrine Pathology)
Source: Endocrine Pathology - October 14, 2022 Category: Pathology Source Type: research
The Significance of RAS-Like Mutations and MicroRNA Profiling in Predicting Malignancy in Thyroid Biopsy Specimens
This study aims to retrospectively evaluate institutional experience of Interpace (ThyGeNEXT® and ThyraMIR®; Pittsburgh, PA) testing and to determine the rate of malignancy in resected nodules, stratified by mutational analysis and microRNA profile. Of 1917 fine need aspirations, 140 (7.3%) underwent Interpace testing: 47 (33.6%) were molecular-not-benign (harbored mutation, fusion, and/or positive miRNA) and 93 (66.4%) were molecular-benign (no mutations or fusions and negative microRNA). Surgery was spared in 79.6% of molecular-benign and 61.4% of all tested patients. Fifty-four (38.6%) underwent resection. Seventeen (...
Source: Endocrine Pathology - October 13, 2022 Category: Pathology Source Type: research
